...New Zealand, and Australia cybersecurity agencies. DataBreaches.net In more cheerful news, Whoop announced that the FDA closed an investigation into their wearable’s Blood Pressure Insights feature. This started with a letter from FDA’s Center for Devices and Radiological Health (CDRH) in July 2025 challenging Whoop on the basis that the company did not have an approved application for premarket approval (PMA) or 510(k) approval of that feature. Apparently, Whoop backed off of original claims that the BPI offered medical-grade health and performance insights and moved to general wellness claims ‘not intended for medical use’. It didn’t dissuade funders from a... Continue Reading
Search Results for fda mobile health
News roundup: VSee refocuses business, transitions CEO; legacy PERS connectivity problems; South Korea’s AI ‘Talking Buddy’, expands telemedicine to foreign patients; Novellia’s $18M Series A
...consultations and follow-up care at clinic or hospital-level medical institutions, continuous observations, counseling, education, diagnosis, and prescriptions. Healthcare IT News Novellia garners $18 million Series A. The funding round for the New York-based company was led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing Novellia’s total funding to $28 million. Their platform is targeted to patients with serious or chronic conditions, helping them to pull all their data from various health providers, add information, digitize paper records, and overall control their health history. Novellia most recently introduced a mobile app platform. The fresh... Continue Reading
Chutes & Ladders: MA sues UHG on Medicaid fraud, Teladoc joins Walmart’s Better Care Services, raises for Signos and H1
...some freeing up of investment cash for companies that have gone through a few (or more than a few) rounds. Glucose monitoring system Signos raised a $20 million round. The investment is from GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. Funding to date including this round is $57 million. Signos is also a partner with Dexcom through their direct-to-consumer continuous glucose monitoring website, Stelo.com. Signos’ app for tracking glucose for weight management is FDA-cleared and includes insights into how behavior, lifestyle, sleep, and stress affect weight. It can also detect low and high glucose levels. Membership... Continue Reading
Post-holiday news roundup: Oracle Health acute care EHR market share crumbles to 20%–what that means; retail real estate downsizer marketing Walgreens leases; Oura files for US IPO, Swoop buys NimbleRx
...Veri in 2024, and Proxy in 2023. Last October, FDA authorized a trial with Oura users of a new blood pressure feature. It also has partnerships in women’s health and hormone tracking. Most recently, last week Oura announced a partnership with Resmed, giving users access to a sleep assessment and educational resources. Oura release, Healthcare Dive, Mobihealthnews Swoop just scooped up NimbleRx. Acquisition cost was not disclosed. Swoop is a data platform for life sciences companies that enables marketing to both patients and healthcare providers, engaging them via targeting, community engagement, AI-powered web solutions, coordinated omnichannel activation, and now prescription... Continue Reading
A quickie news roundup: ChatGPT for Clinicians unveiled, UHG to invest $1.5B in AI, Aidoc raises $150M, TriFetch raises $1.9M pre-seed, Boehringer Ingelheim & Eko Health partner on canine heart murmur detection
...led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors and NVentures (NVIDIA’s venture capital arm). The fresh funds will be used to grow global presence and expand into other clinical areas. FDA clearance for its AI triage tool was gained in January. Mobihealthnews, Release TriFetch has a healthy pre-seed round. A $1.9 million pre-seed these days is rather unusual but TriFetch, an AI automation platform built for independent specialty clinics just emerging from stealth, nabbed it from Nexus Venture Partners, with participation from angels with backgrounds at Google, Hippocratic, Mercor, and MIT. TriFetch’s... Continue Reading
News roundup: (breaking) IKS Health finalizes TruBridge buy, Hims shares rise on independent Rx fills, Cala Health scores $50M, Joyful Health $22M, Tava Health $40M, actor Jeremy Renner partners with RapidSOS
...commercials on 2025’s Super Bowl that their obesity drugs are priced “for profits, not patients”, Hims & Hers has flipped the script in less than a year to be the online prescriber of nearly all brand name weight loss drugs. This started about five months after the Super Bowl when FDA finalized the ban on compounding those drugs. Pretty soon Hims was inking deals, starting with Novo Nordisk in May 2025 to prescribe Wegovy and fulfill through NovoCare Pharmacy. In March, they settled their long-running legal tiff with Novo when they agreed to drop their just-debuted compounded pill to sell... Continue Reading
Chutes & Ladders: Vendor protest filed against VA-OIT, Teladoc stock touted as ‘best buy’, Treehub ‘founder residency’ launches, AcuityMD raises $80M to near-$1B valuation
...announced a raise of $80 million in a Series C led by existing investor StepStone Group, with additional participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. Previous investment was $76 million. The company’s valuation is nearing the $1 billion mark at $955 million. AcuityMD’s platform helps medtech companies towards commercial insights that are typically scattered across claims databases, FDA filings, government records, and market signals. The fresh funding will be used to accelerate platform capabilities via AI. The company claims as customers 16 of the top 20 medtech companies and helping to identify $34 billion in pipeline. Release, Mobihealthnews... Continue Reading
Chutes & Ladders: Click Therapeutics raises $50M, lays off 27%; India’s IKS Health in talks to buy TruBridge for over $600M; TELCOR buys Sample for RCM expansion
...about the potential of CT-155, that shift means making hard changes to our team to match our new commercial mission. These were not decisions we made lightly, and we are deeply grateful to everyone who helped us reach this stage.” CT-155, as it is formally known, does not yet have FDA clearance. It has a Phase III study, CONVOKE (NCT05838625), a Phase III, multicenter, randomized, double-blind, 16-week study evaluating the efficacy and safety of CT-155 versus a digital control app. Neither the BHB and FierceBiotech articles nor Click’s release reveal a timeline for FDA clearance and marketing. Which means that... Continue Reading
Funding/deal roundup: WHOOP’s $575M Giant raise, Anthropic buys med AI startup for $400M, early stage fundings for Jimini, Insight Health; Noom buys compounder; Mount Sinai NY to embed OpenEvidence
...Promus Ventures, and Bullhound Capital alongside a group of prominent global athletes and individual investors. The additional funds will be used for growth in the US plus international expansion across Europe, the GCC, Latin America, and Asia. The wonderfully subjective (by investors) metric of valuation stands at $10.1 billion. Total funding since 2012 is over $900 million. WHOOP received the infamous Warning Letter from FDA’s Center for Devices and Radiological Health (CDRH) in July 2025 regarding marketing claims for Blood Pressure Insights (BPI) on the basis that the company did not have an approved application for premarket approval (PMA) or... Continue Reading
NY Times’ highly questionable but glowing–and viral–portrait of AI-created GLP-1 e-prescriber and marketer Medvi
...people’s records–a significant breach of HIPAA that was solved between the discoverer and an assistant at Medvi–but apparently never reported to HHS’ Office of Civil Rights as required. Medvi received one of those charming warning letters from the FDA in February about their website depicting GLP-1 injectables with their name on the syringe (still there) as well as featuring compounded weight loss and other meds as ‘FDA-approved’–yes, those compounded GLP-1’s no longer permitted for well over a year, and in any case, not approved. [TTA 12 Mar]. There is no record on the FDA website of a response (required within... Continue Reading
Most Recent Comments